Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.

Canadian Retinal Trials Group

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Age-Related Macular Degeneration

Treatments: Drug: Triamcinolone Acetonide

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00148551

01 (C03 - 0236)

Details and patient eligibility

About

A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.

Full description

This study will evaluate the effect of Triamcinolone Acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular degeneration.

Enrollment: 120 estimated patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Individuals with predominantly classic, subfoveal CNV secondary to AMD.
• No previous PDT Treatment in study eye.

Exclusion criteria

• CNV from conditions, other than AMD.
• Other disease that could be responsible for decreased vision.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind